1. Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022

   • Ryosuke Kuribayashi
   • Ayuki Nakano
   • Futaba Honda

   Leading Article 25 May 2023 Pages: 443 - 451

   

2. Base Editing and Prime Editing: Potential Therapeutic Options for Rare and Common Diseases

   • Lauren C. Testa
   • Kiran Musunuru

   Review Article 14 June 2023 Pages: 453 - 462

   

3. Lupus Nephritis: New and Emerging Biologic and Targeted Therapies

   • Ajinath Kale
   • Maciej Lech
   • Anil Bhanudas Gaikwad

   Review Article 24 April 2023 Pages: 463 - 475

   

4. The Role of Biologics in the Treatment of Chronic Rhinosinusitis

   • Nora Haloob
   • Katerina Karamali
   • Claire Hopkins

   Review Article 15 June 2023 Pages: 477 - 487

   

5. Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma

   • Saïf Eddine Zaidi
   • Eliese Moelker
   • Mustafa Khasraw

   Review Article 31 May 2023 Pages: 489 - 503

   

6. Antibody–Drug Conjugates in the Treatment of Urothelial Cancer

   • Avani M. Singh
   • Jose A. Guevara-Patino
   • Rohit K. Jain

   Review Article 31 May 2023 Pages: 505 - 520

   

7. CAR-T Cells and the Kidney: Insights from the WHO Safety Database

   • Alexandre O. Gérard
   • Diane Merino
   • Milou-Daniel Drici

   Original Research Article Open access 11 May 2023 Pages: 521 - 530

   

8. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans

   • Tianzhou Yu
   • Shihan Jin
   • Jakub P. Hlávka

   Original Research Article Open access 01 April 2023 Pages: 531 - 540

9. Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor

   • Jette A. van Lint
   • Naomi T. Jessurun
   • Bart J. F. van den Bemt

   Original Research Article Open access 03 April 2023 Pages: 541 - 550

   

10. Assessing the Interchangeability of AVT02 and Humira^® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study

    • Steven R. Feldman
    • Richard Kay
    • Fausto Berti

    Original Research Article Open access 19 May 2023 Pages: 551 - 567

    

11. Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method

    • Hyunsoo Kim
    • Eunkyoung Hong
    • Taekyung Yoo

    Original Research Article Open access 15 April 2023 Pages: 569 - 581